en · de · es · pt
aod-9604-notes.peptides6608.com › Faq › Identity And Research Origin — Explained

Identity And Research Origin — Explained

By Editorial Desk · published 2025-08-05 · last reviewed 2025-09-18 · Faq

regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-09-18. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Research Origin

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Measurement and Storage Practices

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Aod-9604 at a glance

PropertyValueNotes
Molecular classPeptide fragmentCorresponds to hGH residues 176-191
Common synonymsAOD9604, hGH 176-191Also written as AOD-9604
Typical formLyophilized powderOften supplied in sealed vials
SolubilityWater-solubleDissolves in aqueous buffers
Regulatory statusNot approved as drugBanned in sport; varies by country

Regulatory and Analytical Context

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Related pages on this site

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

Regulation and Detection Context

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

Background from the literature

The left side of the equation describes acceleration, and may be composed of time-dependent and convective components (also the effects of non-inertial coordinates if present). The right side of the equation is in effect a summation of hydrostatic effects, the divergence of deviatoric stress and body forces (such as gravity). All non-relativistic balance equations, such as the Navier–Stokes equations, can be derived by beginning with the Cauchy equations and specifying the stress tensor through a constitutive relation. By expressing the deviatoric (shear) stress tensor in terms of viscosity and the fluid velocity gradient, and assuming constant viscosity, the above Cauchy equations will lead to the Navier–Stokes equations below.

Plastination is a technique or process used in anatomy to preserve bodies or body parts, first developed by Gunther von Hagens in 1977. The water and fat are replaced by certain plastics, yielding specimens that can be touched, do not smell or decay, and even retain most properties of the original sample.

== Initiatives around the globe == In the United States in 2006, JDRF (formerly the Juvenile Diabetes Research Foundation) launched a multi-year initiative to help accelerate the development, regulatory approval, and acceptance of continuous glucose monitoring and artificial pancreas technology. Grassroots efforts to create and commercialize a fully automated artificial pancreas system have also arisen directly from patient advocates and the diabetes community. In April 2024, the NHS announced it would, over the next five years, offer use of a Hybrid Closed Loop system to Type 1 diabetes patients in England.

One of the first adoptions of the trope is Rachel Pollack's Tree House (1984). The titular megaflora in Larry Niven's 1984 novel The Integral Trees exist within an orbiting gaseous torus full of life adapted to free-fall. The concept is discussed in Carl Sagan and Ann Druyan's 1985 non-fiction book Comet, and several paintings of Dyson trees around Saturn and in interstellar space are provided in the book by Jon Lomberg. In Michael Swanwick's 1987 transhumanist novel Vacuum Flowers, "dysonsworlders" have established tree settlements in the Oort Cloud. Under the name of "Space Poplars", Dyson trees are described in Donald Moffitt's two science fiction novels, The Genesis Quest and Second Genesis. Here they are used as both habitats and spacecraft, propelled by reflective outer leaves used as organic solar sails. Dan Simmons, in Endymion (1996) and the Rise of Endymion (1997) – both part of his Hyperion Cantos – refers to Dyson trees, and in the latter novel to a huge tree system that surrounds an entire star (reminiscent of a Dyson sphere). In Stephen Baxter's Manifold: Space (2001), Baxter's protagonist Reid Malenfant at one point finds himself inside a Dyson tree. In the Orion's Arm shared universe (established 2000), Dyson trees and Dyson tree "forests" are called orwoods; these have been established in a number of star systems throughout terragen space. The word "Orwood" in this context was originally coined by Anders Sandberg. The Transhuman Space roleplaying game includes the beginning of a Dyson tree endeavour on Yggdrasil Station.

Sources: en.wikipedia.org

Further detail

=== June 2006 === According to the Iraqi Defense Ministry, Private First Class Thomas Tucker and Private First Class Kristian Menchaca were reportedly "killed in a barbaric way," "slaughtered," and tortured to death, and their bodies were so mutilated that DNA tests are being performed to help identify their remains. The alleged group has said it was a revenge for the rape and murder of an Iraqi girl who was dishonoured by soldiers of the same brigade. Video of the killing of four Russian diplomats kidnapped in Iraq appear on the Internet. A group called the Mujahideen Shura Council released the hostage video.

Phytoplankton, also known as microscopic algae. Free-floating; drifting with water currents. Periphyton - a microphyte that lives and grows on the surface of rooted aquatic plants. Benthic algae - relatively immobile algae that inhabit the submerged substrate surface of freshwater on mud, stones, or other relatively stable material. Algae may be single celled such as diatoms or Desmids, or multi-celled such as Spirogyra or Cladophora. A few such as some of the diatoms have limited abilities to move over their substrate.

carrier protein 1. A membrane protein that functions as a transporter, binding to a solute and facilitating its movement across the membrane by undergoing a series of conformational changes. 2. A protein to which a specific ligand or hapten has been conjugated and which thereby carries an antigen capable of eliciting an antibody response. 3. A protein which is included in an assay at high concentrations in order to prevent non-specific interactions of the assay's reagents with vessel surfaces, sample components, or other reagents. For example, in many blotting techniques, albumin is intentionally allowed to bind non-specifically to the blotted membrane prior to fluorescent labelling, so as to "block" potential off-target binding of the fluorophore to the membrane, which might otherwise cause background fluorescence that obscures genuine signal from the target.

Sources: en.wikipedia.org

Supporting material

Watson was selected at pick 40 under the father–son rule in the 2002 national draft. He was initially coached as a key forward by Kevin Sheedy, who also coached his father Tim. His poor kicking by AFL standards drew criticism, and it was determined that he would be more suited to the midfield at Essendon. At the time, his weight was criticised by the media, as he was overweight for an AFL player. Over the next two seasons, he began to develop his craft in the Essendon midfield and became one of the competition's elite midfielders. Watson had a consistent season in 2009, polling ten Brownlow Medal votes and winning the Essendon best-and-fairest award, the Crichton Medal. Watson polled 335 votes in 15 of the 21 games he played in the 2009 season, with only one game missed due to an ankle injury. Watson was 46 votes ahead of runner-up Dustin Fletcher, who polled 289 votes. By the end of the 2009 season, Watson had gathered a reputation as Essendon's most important midfielder (coming first in the club's overall clearances) and improved his once-criticised kicking ability to above the standard of an AFL player. Watson was announced as Essendon captain on 21 December 2009, taking over from retired goalkicker Matthew Lloyd. Despite Essendon suffering a disappointing 2010 season, winning only seven games and finishing 14th on the AFL ladder, Watson enjoyed a successful first year as captain.

The birth of most Mexican drug cartels is traced to former Mexican Judicial Federal Police agent Miguel Ángel Félix Gallardo (Spanish: El Padrino, lit. 'The Godfather'), who founded the Guadalajara Cartel in 1980 and controlled most of the illegal drug trade in Mexico and the trafficking corridors across the Mexico–U.S. border along with Juan García Ábrego throughout the 1980s. He started by smuggling marijuana and opium into the U.S., and was the first Mexican drug chief to link up with Colombia's cocaine cartels in the 1980s. Through his connections, Félix Gallardo became the person at the forefront of the Medellín Cartel, which was run by Pablo Escobar. This was accomplished because Félix Gallardo had already established a marijuana trafficking infrastructure that stood ready to serve the Colombia-based cocaine traffickers. There were no other cartels at that time in Mexico. He oversaw operations with his cronies and the politicians who sold him protection. The Guadalajara Cartel suffered a major blow in 1985 when the group's co-founder Rafael Caro Quintero was captured, and later convicted, for the murder of DEA agent Enrique "Kiki" Camarena. Félix Gallardo then kept a low profile and in 1987 he moved with his family to Guadalajara. According to Peter Dale Scott, the Guadalajara Cartel prospered largely because it enjoyed the protection of the Dirección Federal de Seguridad (DFS), under its chief Miguel Nazar Haro. Félix Gallardo was arrested on April 8, 1989.

== Awards and honors == Strobel has received Beckman, Searle and Basil O'Connor career awards. He received the Dylan Hixon Prize for Teaching Excellence in the Natural Sciences. He also received the Yale Graduate Mentoring Award in the Sciences. He received the Yale Science and Engineering Association Award for Meritorious Service to Yale University.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.

Is AOD-9604 the same as growth hormone?

No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.

How is AOD-9604 regulated?

Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.

How is AOD-9604 typically analyzed?

Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.

Network